Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Chrysalin · TP 508, TP-508 ACETATE

Peptide · developed by Capstone Therapeutics

Phase 2 Most advanced trial (none active)
CAPS Developer
1 Registered trials

What is Chrysalin?

Chrysalin (TP 508) is a peptide administered by percutaneous injection at the fracture site at the time of surgery. It has been studied in radius fracture, a bone injury of the forearm.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TP 508, TP-508 ACETATE, TRAP-508 ACETATE
Drug type
Peptide
Therapy area
Musculoskeletal
Developer
Capstone Therapeutics (CAPS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
9J556O9JPD

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00131482 Phase 2 Radius Fracture Terminated CAPS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Radius Fracture

More from Capstone Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CAPS page.

Follow CAPS, the company behind Chrysalin

See CAPS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CAPS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.